MET-815

MET-815 is a **synthetic peptide** and a **prodrug** of MET-097i, a fully biased, ultra-long acting GLP-1 receptor agonist developed for obesity and metabolic disorders. It is designed to smooth the onset of drug exposure and substantially prolong time above clinically meaningful exposure thresholds, with the goal of providing **less frequent dosing (potential for quarterly maintenance dosing)** and improved tolerability compared to current GLP-1 receptor agonists. Its primary mechanism of action is **agonism of the glucagon-like peptide 1 receptor (GLP-1R)**, making it part of the next-generation nutrient-stimulated hormone (NuSH) analogs pipeline[1][2][3][6].

Other names

MET-815MET815MET 815MET-815iMET815iMET 815i